ISB-1442 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISB-1442’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ISB-1442 overview

ISB-1442 is under development for the treatment of T-cell acute lymphoblastic leukemia (T-ALL), relapsed/refractory multiple myeloma, relapsed/refractory acute myeloid leukemia. It acts by targeting CD38 and CD47.The drug candidate is developed based on BEAT (Bi-specific Engagement by Antibodies based on the T cell receptor) platform. It is a new biological entity (NBE). It is administered through subcutaneous route.

Ichnos Glenmark Innovation overview

Ichnos Glenmark Innovation specializes in research and development of novel cutting-edge therapeutics for the treatment of cancer. The company is headquartered in New York City, New York, the US.

For a complete picture of ISB-1442’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.